Review
Cell Biology
Hong-Bo Li, Zi-Han Yang, Qing-Qu Guo
Summary: Pancreatic cancer is a highly malignant tumor with poor therapeutic outcomes, and immune checkpoint inhibitors have limited efficacy in treating PDAC due to its inhibitory immune microenvironment. Strategies to enhance the efficacy of ICIs in PDAC treatment by targeting the tumor microenvironment are currently being explored.
CELL COMMUNICATION AND SIGNALING
(2021)
Article
Oncology
Mineyoshi Sato, Nako Maishi, Yasuhiro Hida, Aya Yanagawa-Matsuda, Mohammad Towfik Alam, Jun Sakakibara-Konishi, Jin-Min Nam, Yasuhito Onodera, Satoshi Konno, Kyoko Hida
Summary: In lung cancer, immune checkpoint inhibitors (ICIs) alone are not sufficient for inhibiting tumor growth. Angiogenic inhibitors (AIs) are needed to normalize tumor blood vessels for better immune cell infiltration. This study examined the effects of pre-administering an AI for lung cancer immunotherapy in a mouse model. Pre-administration of the AI improved immune cell infiltration and enhanced the therapeutic effects of ICIs.
Review
Immunology
Patrizia Leone, Antonio Giovanni Solimando, Rossella Fasano, Antonella Argentiero, Eleonora Malerba, Alessio Buonavoglia, Luigi Giovanni Lupo, Valli De Re, Nicola Silvestris, Vito Racanelli
Summary: Hepatocellular carcinoma is a common and deadly cancer around the world. Traditional treatments like surgery, radiotherapy, and targeted therapies have been used, but due to the immune suppressive nature of HCC, immunotherapy with immune checkpoint inhibitors has shown great promise in recent clinical studies.
Article
Oncology
Minjiang Chen, Pengfei Ma, Yongchang Zhang, Dong Wang, Zhuang Yu, Yujie Fu, Xiaojing Zhao, Mengzhao Wang, Guanglei Zhuang, Ying Jing
Summary: Our study provides insights into the immune hallmarks associated with response and immune-related adverse events (irAEs) in lung squamous cell carcinoma (LUSC) patients receiving immune checkpoint inhibitors (ICIs). We found specific reprogramming of macrophage, T cells, and tumor cells associated with ICI response and irAEs, elucidated divergent roles of TNF signaling in antitumor immunity and irAEs, and highlighted the significance of TNF expression in irAE development in the LUSC setting.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Chemistry, Multidisciplinary
Guangnian Liu, Wenping Huang, Lin Chen, Nilupaier Tayier, Liwei You, Muhammad Hamza, Xiaodong Tian, Hai Wang, Guangjun Nie, Motao Zhu, Yinmo Yang
Summary: A high-yielding method using hybrid nanovesicles derived from bacteria has been developed to improve cancer immunotherapy. These nanovesicles have superior targeting abilities, activate immune responses, and reshape the tumor microenvironment, leading to effective inhibition of tumor growth in pancreatic cancer mouse models when combined with PD-1 blockade therapy.
Article
Oncology
Sasitorn Yenyuwadee, Konstantinos Aliazis, Qi Wang, Anthos Christofides, Rushil Shah, Nikolaos Patsoukis, Vassiliki A. Boussiotis
Summary: In the past decade, antibody-based and cell-based immunotherapies have revolutionized cancer therapeutics by modulating immune responses against tumors. However, the full potential of immunotherapy has not been reached due to incomplete knowledge of the cellular and molecular mechanisms involved in successful anti-tumor immunity and immune escape.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Oncology
Ryan C. Augustin, Sarah Newman, Aofei Li, Marion Joy, Maureen Lyons, Mary P. Pham, Peter Lucas, Katelyn Smith, Cindy Sander, Brian Isett, Diwakar Davar, Yana G. Najjar, Hassane M. Zarour, John M. Kirkwood, Jason John Luke, Riyue Bao
Summary: In this study, we characterized acral melanoma (AM) and investigated its response to immune checkpoint inhibitors (ICIs). We found differential gene expression and pathway activation in a non-T cell-inflamed tumor microenvironment (TME) of AM, which may contribute to its poor response to ICIs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Pharmacology & Pharmacy
Yang Wen, Anqi Lin, Weiliang Zhu, Ting Wei, Peng Luo, Linlang Guo, Jian Zhang
Summary: The study found that CTNNA2 gene mutation is associated with longer overall survival in LUAD patients and is linked to increased tumor neoantigens and tumor mutation burden. CTNNA2 mutation may have therapeutic effects by altering the immune microenvironment.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Yanan Cui, Xinyin Liu, Yuemin Wu, Xiao Liang, Jiali Dai, Zhihong Zhang, Renhua Guo
Summary: Immune checkpoint inhibitors have limited efficacy in non-small cell lung cancer patients, and there is a need for reliable predictive markers. This study identified AHNAK2 mutation as a potential biomarker for predicting favorable response to ICI treatment in NSCLC patients.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Nicolas Huyghe, Elena Benidovskaya, Philippe Stevens, Marc Van den Eynde
Summary: ICIs are effective in Microsatellite Instability High Colorectal Cancer (MSI-H CRC), but have limited clinical benefit in Microsatellite Stable (MSS) CRC. Efforts are being made to understand the heterogeneous CRC microenvironment and find predictive biomarkers for selecting CRC patients who may respond to ICIs-based therapies. Trials are also being conducted to study new biomarkers and treatments targeting immune checkpoint molecules to improve response in MSS CRC.
Review
Immunology
Basak Aru, Cemil Pehlivanoglu, Zeynep Dal, Nida Nur Dereli-Caliskan, Ege Gurlue, Guelderen Yanikkaya-Demirel
Summary: Acute myeloid leukemia (AML) is the most common leukemia type in adults, accounting for 80% of all cases. The current treatment options for AML mainly include chemotherapy, with rare cases considering radiotherapy and stem cell and bone marrow transplantation. Immune checkpoint inhibitors (ICIs) have shown promise in supporting anti-tumor immunity by targeting negative immune regulation. The interactions between blood cell lineages and the noncellular components of the bone marrow microenvironment (BMM) play a crucial role in AML development and progression. This review discusses the potential application of ICIs in AML treatment by regulating the BMM.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Yaping Chen, Hao Huang, Yuan Li, Wenlu Xiao, Yingting Liu, Rongzhang Chen, Yulan Zhu, Xiao Zheng, Changping Wu, Lujun Chen
Summary: Combination immunotherapy based on immune checkpoint inhibitors (ICIs) has shown great success in cancer treatment, and the combination of ablation and immunotherapy has potential for the treatment of liver metastasis of colorectal cancer (CRC). The expression of TIGIT was up-regulated after microwave ablation (MWA), and the combination of MWA and TIGIT blockade significantly promoted the expansion and functions of CD8(+) tumor-infiltrating lymphocytes (TILs) and reshaped myeloid cells in the tumor microenvironment (TME).
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Deqiang Wang, Xiaofeng Chen, Yian Du, Xiaoqin Li, Leqian Ying, Yi Lu, Bo Shen, Xuan Gao, Xin Yi, Xuefeng Xia, Xinbing Sui, Yongqian Shu
Summary: HER2 mutations may improve the tumor microenvironment to promote immunotherapy. A prospective basket trial is needed to further investigate the impacts of HER2 mutations on immunotherapy outcomes in solid tumors.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Chemistry, Medicinal
Habib Sadeghi Rad, James Monkman, Majid E. Warkiani, Rahul Ladwa, Ken O'Byrne, Nima Rezaei, Arutha Kulasinghe
Summary: Advances in immunotherapy have provided durable and long-term benefits for certain patients with solid tumors, with a key focus on understanding the immune landscape of the tumor microenvironment to develop effective immunotherapeutic strategies.
MEDICINAL RESEARCH REVIEWS
(2021)
Article
Immunology
Xiaoling Shang, Wengang Zhang, Xun Zhang, Miao Yu, Jingwen Liu, Yufeng Cheng, Bo Cheng
Summary: The study found that PTPRD/PTPRT mutations may be potential biomarkers for predicting the responsiveness of ICI treatment in multiple cancer types, and are associated with the efficacy of ICIs and patient survival.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Ying-Chun Shen, Ali Ghasemzadeh, Christina M. Kochel, Thomas R. Nirschl, Brian J. Francica, Zoila A. Lopez-Bujanda, Maria A. Carrera Haro, Ada Tam, Robert A. Anders, Mark J. Selby, Alan J. Korman, Charles G. Drake
PROSTATE CANCER AND PROSTATIC DISEASES
(2018)
Article
Biochemistry & Molecular Biology
Hui-Chen Wu, Catherine Do, Irene L. Andrulis, Esther M. John, Mary B. Daly, Saundra S. Buys, Wendy K. Chung, Julia A. Knight, Angela R. Bradbury, Theresa H. M. Keegan, Lisa Schwartz, Izabela Krupska, Rachel L. Miller, Regina M. Santella, Benjamin Tycko, Mary Beth Terry
Article
Cell Biology
Clementine Le Magnen, Renu K. Virk, Aditya Dutta, Jaime Yeji Kim, Sukanya Panja, Zoila A. Lopez-Bujanda, Andrea Califano, Charles G. Drake, Antonina Mitrofanova, Cory Abate-Shen
DISEASE MODELS & MECHANISMS
(2018)
Article
Oncology
Grazia Ambrosini, Catherine Do, Benjamin Tycko, Ronald B. Realubit, Charles Karan, Elgilda Musi, Richard D. Carvajal, Vivian Chua, Andrew E. Aplin, Gary K. Schwartz
Meeting Abstract
Oncology
Matthew Dallos, Aleksandar Obradovic, Nivi Chowdhury, Zoila Lopez Bujanda, David Henry Aggen, Jessica Hawley, Dana E. Rathkopf, Charles G. Drake
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Article
Multidisciplinary Sciences
Stephanie Shiau, Renate Strehlau, Shuang Wang, Avy Violari, Catherine Do, Faeezah Patel, Afaaf Liberty, Izabela Krupska, Stephen M. Arpadi, Marc Foca, Ashraf Coovadia, Elaine J. Abrams, Benjamin Tycko, Mary Beth Terry, Louise Kuhn
SCIENTIFIC REPORTS
(2019)
Article
Biology
Anita V. Devineni, Bei Sun, Anna Zhukovskaya, Richard Axel
Article
Biochemical Research Methods
Emmanuel L. P. Dumont, Benjamin Tycko, Catherine Do
Article
Endocrinology & Metabolism
Jessica E. Hawley, Samuel Pan, William D. Figg, Zoila A. Lopez-Bujanda, Jonathan D. Strope, David H. Aggen, Matthew C. Dallos, Emerson A. Lim, Mark N. Stein, Jianhua Hu, Charles G. Drake
Article
Genetics & Heredity
Ming Li, Chen Lyu, Manyan Huang, Catherine Do, Benjamin Tycko, Philip J. Lupo, Stewart L. MacLeod, Christopher E. Randolph, Nianjun Liu, John S. Witte, Charlotte A. Hobbs
Summary: The study found that genetic variants may influence the risk of CHDs by regulating changes in DNA methylation and gene expression, providing new insights into the pathogenesis of CHDs. The results can be integrated with other genetic studies of heart diseases, especially CHDs, and are significant for the prevention and treatment of CHDs.
Article
Biotechnology & Applied Microbiology
Catherine Do, Emmanuel L. P. Dumont, Martha Salas, Angelica Castano, Huthayfa Mujahed, Leonel Maldonado, Arunjot Singh, Sonia C. DaSilva-Arnold, Govind Bhagat, Soren Lehman, Angela M. Christiano, Subha Madhavan, Peter L. Nagy, Peter H. R. Green, Rena Feinman, Cornelia Trimble, Nicholas P. Illsley, Karen Marder, Lawrence Honig, Catherine Monk, Andre Goy, Kar Chow, Samuel Goldlust, George Kaptain, David Siegel, Benjamin Tycko
Article
Oncology
Zoila A. Lopez-Bujanda, Matthew G. Chaimowitz, Todd D. Armstrong, Jeremy B. Foote, Leisha A. Emens, Charles G. Drake